NCT01612273 is a Phase 4 clinical trial of Triflusal in Vasospastic Syndrome, sponsored by Yonsei University.

Who is sponsoring NCT01612273?

NCT01612273 is sponsored by Yonsei University.

What drugs are being tested in NCT01612273?

Interventions in NCT01612273: Triflusal, Aspirin.

What condition does NCT01612273 study?

NCT01612273 studies Vasospastic Syndrome.

Is NCT01612273 still recruiting?

NCT01612273 is currently completed. Last updated 4 March 2014.

Last reviewed 2014-03-04 · How we verify

NCT01612273

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Triflusal on Peripheral Microcirculation Dysfunction: A Double-Blind, Randomized, Controlled, Crossover Study.

Completed Phase 4 Last updated 4 March 2014

What this trial tests

Phase 4 trial testing Triflusal in Vasospastic Syndrome in 92 participants. Completed in 1 June 2013.

Timeline

1 April 2011

Primary endpoint
1 January 2013

1 June 2013

Quick facts

Lead sponsor	Yonsei University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	92
Start date	1 April 2011
Primary completion	1 January 2013
Estimated completion	1 June 2013
Sites	1 location across South Korea

Drugs / interventions tested

Triflusal (TRIFLUSAL) — full drug profile →
Aspirin — full drug profile →

Conditions studied

Vasospastic Syndrome — all drugs for Vasospastic Syndrome →

Sponsor

Yonsei University

Who can join

Adults 40 to 70, any sex, with Vasospastic Syndrome. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Primary Outcome - The amount of blood flow measured by finger doppler ultrasonography. The improvement of subjective symptom measured by questionaire.
Time frame: 6 weeks
Comparison of the PSV (peak systolic velocity) and EDV (end diastolic velocity) measured by finger doppler ultrasonography between disgren and aspirin groups after 6 weeks treatment.

Sponsor's own description

To explore the efficacy of triflusal in patients with symptomatic peripheral microcirculation dysfunction. Triflusal is a salicylate compound approved in several countries as antithrombotic agent and it additionally has vasodilatory effect. The hypothesis is to explore if there is a improvement of peripheral microcirculation by triflusal.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial.
Shin S, Kim KJ, Cho IJ, Hong GR, et al · · 2015 · cited 1× · PMID 26256964 · DOI 10.3349/ymj.2015.56.5.1227

Verify or expand the search:

Other trials of Triflusal

Trials testing the same drug.

NCT02904109 — Influence of Triflusal on Cognitive Functions in Subjects Under Chronic Stress · Phase 2 · completed

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01612273 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 4 March 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01612273.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing